Medivir is a pharmaceutical company focusing on the development of innovative treatments for cancer.
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.Partnership >
Medivir to present at the Pareto Securities Healthcare ConferenceRead more
Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical studyRead more
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCARead more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.